Corvention Receives FDA Clearance for Innovative KardiaPSI Balloon Catheter Designed for Aortic Valve Dilation
In a significant advancement for cardiac healthcare, Corvention has announced that its KardiaPSI™ Balloon Catheter has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This innovative device is poised to transform the approach to balloon aortic valvuloplasty (BAV) by offering interventional cardiologists an ultra high-pressure solution specifically designed for the meticulous dilation of calcified aortic valves.
Advancing Cardiac Interventions
The KardiaPSI™ Balloon Catheter marks a pivotal development within the heart medical device sector, as it incorporates advanced engineering aimed at overcoming the challenges faced during valvuloplasty procedures. The catheter can deliver an extraordinary 24 atm of pressure, optimizing the dilation process while maintaining safety and precision, thanks to its carefully engineered 2.5 cm working length. This feature allows healthcare professionals to perform procedures that require both strength and finesse to navigate the complexities of calcified valve anatomy.
Executive Insights
Michael Franklin, CEO and Co-Founder of Corvention, articulates the transformative nature of this device. He notes, "The KardiaPSI™ Balloon Catheter was developed to solve the fundamental challenges associated with valvuloplasty—the persistent issue of delivering sufficient force in a controlled manner when dealing with calcified morphologies." Franklin emphasizes that with the introduction of the KardiaPSI, physicians will have access to reliable, high-performance tools that expand possibilities in complex interventions.
Dr. Scott Lim, the Chair of Corvention's Advisory Board, echoes this sentiment, stating, "We identified the need for a compact yet powerful BAV solution. The KardiaPSI™ technology aptly addresses this necessity, and with FDA clearance, we are taking a step closer to making this appliance a standard in the toolkit for structural heart interventions."
Path to Market
With the pivotal regulatory endorsement achieved, Corvention is spearheading a structured introduction of the KardiaPSI™ Balloon Catheter into the market. The company is dedicated to building the necessary commercial framework and providing the strategic support essential for a smooth national launch. This approach ensures that clinical support and physician training are prioritized, laying the groundwork for the successful integration of this technology into medical practices across the country.
The KardiaPSI™ Advantage
About Corvention
Founded in 2021, Corvention is based in Flagstaff, Arizona, and specializes in creating advanced tools specifically for structural heart interventions in catheterization laboratories. The firm is committed to enhancing clinical safety, efficacy, and the overall predictability of cardiovascular procedures, particularly those involving intricate anatomical challenges. For further inquiries or to learn more about their groundbreaking products, prospective clients and medical professionals can visit Corvention's website at www.corvention.com.
Advancing Cardiac Interventions
The KardiaPSI™ Balloon Catheter marks a pivotal development within the heart medical device sector, as it incorporates advanced engineering aimed at overcoming the challenges faced during valvuloplasty procedures. The catheter can deliver an extraordinary 24 atm of pressure, optimizing the dilation process while maintaining safety and precision, thanks to its carefully engineered 2.5 cm working length. This feature allows healthcare professionals to perform procedures that require both strength and finesse to navigate the complexities of calcified valve anatomy.
Executive Insights
Michael Franklin, CEO and Co-Founder of Corvention, articulates the transformative nature of this device. He notes, "The KardiaPSI™ Balloon Catheter was developed to solve the fundamental challenges associated with valvuloplasty—the persistent issue of delivering sufficient force in a controlled manner when dealing with calcified morphologies." Franklin emphasizes that with the introduction of the KardiaPSI, physicians will have access to reliable, high-performance tools that expand possibilities in complex interventions.
Dr. Scott Lim, the Chair of Corvention's Advisory Board, echoes this sentiment, stating, "We identified the need for a compact yet powerful BAV solution. The KardiaPSI™ technology aptly addresses this necessity, and with FDA clearance, we are taking a step closer to making this appliance a standard in the toolkit for structural heart interventions."
Path to Market
With the pivotal regulatory endorsement achieved, Corvention is spearheading a structured introduction of the KardiaPSI™ Balloon Catheter into the market. The company is dedicated to building the necessary commercial framework and providing the strategic support essential for a smooth national launch. This approach ensures that clinical support and physician training are prioritized, laying the groundwork for the successful integration of this technology into medical practices across the country.
The KardiaPSI™ Advantage
- - Ultrahigh-Pressure Capability: The device is engineered to withstand the extreme pressures necessary for disrupting significant calcification, ensuring efficacy when dealing with challenging anatomical structures.
- - Precision Sizing Mechanism: Physicians can adjust the dilation process precisely, optimizing treatment based on individual patient anatomy while minimizing interactions with non-target structures.
- - Efficient Procedure Execution: The device boasts fast inflation and deflation capabilities through a single syringe/inflation mechanism, enhancing workflow efficiency in catheterization labs.
About Corvention
Founded in 2021, Corvention is based in Flagstaff, Arizona, and specializes in creating advanced tools specifically for structural heart interventions in catheterization laboratories. The firm is committed to enhancing clinical safety, efficacy, and the overall predictability of cardiovascular procedures, particularly those involving intricate anatomical challenges. For further inquiries or to learn more about their groundbreaking products, prospective clients and medical professionals can visit Corvention's website at www.corvention.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.